Evidence map›Paper›PMID 30976201›Full record

ArticleCancer cell international2019

Overexpression and Tyr421-phosphorylation of cortactin is induced by three-dimensional spheroid culturing and contributes to migration and invasion of pancreatic ductal adenocarcinoma (PDAC) cells.

Katharina Stock, Rebekka Borrink, Jan-Henrik Mikesch, Anna Hansmeier, Jan Rehkämper, Marcel Trautmann, Eva Wardelmann, Wolfgang Hartmann, Jan Sperveslage, Konrad Steinestel

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. A standardized extract of culturedOncology letters · 2021
    Article
  10. Article
  11. Article
  12. Review
  13. Cortactin in Epithelial-Mesenchymal Transition.Frontiers in cell and developmental biology · 2020
    Review
  14. Article
  15. CRISPR Cas9 in Pancreatic Cancer Research.Frontiers in cell and developmental biology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Katharina Stock1Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Rebekka Borrink1Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Jan-Henrik Mikesch2Department of Medicine A, University Hospital Münster, Münster, Germany.
Anna Hansmeier2Department of Medicine A, University Hospital Münster, Münster, Germany.
Jan Rehkämper1Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Marcel Trautmann1Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Eva Wardelmann1Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Wolfgang Hartmann1Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Jan Sperveslage *1Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Konrad Steinestel *1Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
University Hospital Münster · DEBundeswehrkrankenhaus · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe nucleation-promoting factor cortactin is expressed and promotes tumor progression and metastasis in various cancers. However, little is known about the biological role of cortactin in the progression of pancreatic ductal adenocarcinoma (PDAC).

methodsCortactin and phosphorylated cortactin (Y421) were investigated immunohistochemically in 66 PDAC tumor specimens. To examine the functional role of cortactin in PDAC, we modulated cortactin expression by establishing two cortactin knockout cell lines (Panc-1 and BxPC-3) with CRISPR/Cas9 technique. Cortactin knockout was verified by immunoblotting and immunofluorescence microscopy and functional effects were determined by cell migration and invasion assays. A proteomic screening approach was performed to elucidate potential binding partners of cortactin.

resultsImmunohistochemically, we observed higher cortactin expression and Tyr421-phosphorylation in PDAC metastases compared to primary tumor tissues. In PDAC cell lines Panc-1 and BxPC-3, knockdown of cortactin impaired migration and invasion, while cell proliferation was not affected. Three-dimensional spheroid culturing as a model for collective cell migration enhanced cortactin expression and Tyr421-phosphorylation. The activation of cortactin as well as the migratory capacity of PDAC cells could significantly be reduced by dasatinib, a Src family kinase inhibitor. Finally, we identified gelsolin as a novel protein interaction partner of cortactin in PDAC.

conclusionOur data provides evidence that cohesive cell migration induces cortactin expression and phosphorylation as a prerequisite for the gain of an invasive, pro-migratory phenotype in PDAC that can effectively be targeted with dasatinib.

Indexed as

CortactinPancreatic ductal adenocarcinomaTumor cell migration and invasion

Identifiers

PMID30976201
PMCPMC6441202
OpenAlexW2942707354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.